Cowen Upgrades Immunogen Inc. (IMGN) to Outperform
Tweet
Share
E-mailGet Alerts IMGN Hot Sheet
Rating Summary:
5 Buy, 17 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE
Cowen analyst John Scott upgraded Immunogen Inc. (NASDAQ: IMGN) from Market Perform to Outperform.
The analyst comments "On 1Q19 earnings call IMGN noted that all secondary endpoints continue to trend positively in FRa high patients from FORWARD I trial. Here we discuss 3 potential scenarios and implications for IMGN's valuation. Additional clarity should come in 2H19 after the company meets with the FDA. We believe shares are undervalued and are upgrading our rating to Outperform."
For an analyst ratings summary and ratings history on Immunogen Inc. click here. For more ratings news on Immunogen Inc. click here.
Shares of Immunogen Inc. closed at $2.88 yesterday.
Create E-mail Alert Related Categories
Analyst Comments, Hot Upgrades, UpgradesRelated Entities
Cowen & Co, Earnings, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
